Quantitative Concept – Talk Bio

Actionable Insights Powered by AI

Corxel Pharmaceuticals Raises $287M Series D1 to Advance Oral GLP-1 Obesity Drug CX11

2 days ago talkbio0Tagged Corxel Pharmaceuticals, Funding, Glucagon-Like Peptide 1, Obesity Drug, Series D1, Vincentage

Corxel Pharmaceuticals; Series D1; GLP-1; CX11; obesity drug; funding; Vincentage

Novo Offloads Cell Therapy Technologies to Aspect After Retreat from the Field

4 days ago talkbio0Tagged Aspect - Kind of quantity, Cell Therapy, Diabetes Mellitus, Insulin-Dependent, Hypoimmune Technology, Novo Nordisk, stem cell-derived islet cells

Novo Nordisk; Aspect; cell therapy; type 1 diabetes; stem cell-derived islet cells; hypoimmune technology

Genmab and AbbVie’s Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial

6 days ago talkbio0Tagged AbbVie, Diffuse Large B-Cell Lymphoma, DLBCL-1, EPCORE, Epcoritamab, EPKINLY, Genmab, Lymphoma, Overall Survival, Phase 3, Progression-Free Survival

Genmab; AbbVie; epcoritamab; Epkinly; EPCORE DLBCL-1; Phase 3; DLBCL; lymphoma; overall survival; progression-free survival

Trump Unveils ‘The Great Healthcare Plan’ to Lower Drug Prices and Target Insurers

1 week ago talkbio0Tagged drug price, Great Healthcare Plan, Health Care Reform, Insurance Premiums, price transparency, Transplant Registry Unified Management Program

Trump; Great Healthcare Plan; drug pricing; insurance premiums; price transparency; healthcare reform

Caldera Therapeutics Launches with $112.5M Funding for China-Licensed IBD Bispecific Antibody

2 weeks ago talkbio0Tagged Antibodies, Bispecific, Caldera Therapeutics, CLD-423, Funding, Inflammatory Bowel Diseases, Qyuns Therapeutics

Caldera Therapeutics; IBD; bispecific antibody; $112.5M funding; Qyuns Therapeutics; CLD-423

Lightning Step and Sunwave Achieve SOC 2 Type II Attestation, Strengthening Security and Trust Across Healthcare Technology

2 weeks ago talkbio0Tagged Biomechanical compliance, Healthcare technology, Lightning Step, Security - service, spindle orientation checkpoint, Sunwave, Type 2

Lightning Step; Sunwave; SOC 2 Type II; Healthcare Technology; Security; Compliance

Biopharma Bites: Teva, Kinaset Funding Wins, Camzyos Teen Approval, Lynk and Lyra’s Mixed Fortunes

2 weeks ago talkbio0Tagged approvals, Biopharma, Camzyos, Clinical, Funding, Kinaset, Lynk, Structure of hippocampal commissure, Teva

Teva; Kinaset; Camzyos; Lynk; Lyra; biopharma funding; clinical approvals

Kinaset Therapeutics Raises $103M to Advance Inhaled Asthma Drug

2 weeks ago talkbio0Tagged asthma drug, Funding, inhaled therapy, Kinaset Therapeutics, Series A

Kinaset Therapeutics; funding; asthma drug; inhaled therapy; Series A

Speculation builds about a multibillion-dollar takeout of Revolution Medicines

2 weeks ago talkbio0Tagged AbbVie, Acquisition, daraxonrasib, financial, J.P. Morgan Healthcare Conference, Merck, Neoplasms, RAS-driven cancers, Revolution Medicines, rumors, RVMD, takeover talks, Wall Street Journal

Revolution Medicines; RVMD; Merck; AbbVie; takeover talks; acquisition rumors; buyout speculation; Financial Times report; Wall Street Journal; J.P. Morgan Healthcare Conference; multibillion-dollar deal; oncology; RAS-driven cancers; daraxonrasib

Obesity biotech Alveus raises ~$160M Series A to advance MariTide‑like GLP‑1/GIPR drug and amylin pipeline

2 weeks ago talkbio0Tagged * * New Rhein Healthcare Investors, * * Sanofi Capital, ALV-100, ALV-200, Alveus Therapeutics, Amylin, Andera Partners, Antagonist muscle action, GIPR gene, MariTide-like, Metabolic Diseases, Obesity, Omega Funds, Product containing glucagon-like peptide 1 receptor agonist (product), Series

Alveus Therapeutics; obesity biotech; $160 million Series A; ALV-100; MariTide-like; GLP-1 receptor agonist; GIPR antagonist; amylin; ALV-200; obesity drugs; metabolic diseases; Sanofi Capital; New Rhein Healthcare Investors; Andera Partners; Omega Funds